Betta Pharmaceuticals Co., Ltd. (SHE: 300558)

Market Cap	15.44B
Revenue (ttm)	2.64B
Net Income (ttm)	423.67M
Shares Out	418.49M
EPS (ttm)	1.01
PE Ratio	36.51
Forward PE	27.74
Dividend	0.17 (0.46%)
Ex-Dividend Date	Jun 6, 2024

Volume	5,060,800
Open	37.24
Previous Close	37.34
Day's Range	36.63 - 37.80
52-Week Range	30.43 - 63.09
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Betta Pharmaceuticals

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is headquartered in Hangzhou, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 1,961
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300558

Financial Performance

In 2023, Betta Pharmaceuticals's revenue was 2.46 billion, an increase of 3.35% compared to the previous year's 2.38 billion. Earnings were 348.03 million, an increase of 139.33%.